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A LARGE NATIONAL COMMERCIAL PAYOR DATABASE
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HCT is a resource-intense and expensive procedure. Single insti-
tution studies have described costs of HCT; however, costs from the
national perspective are not well known. We used a large US com-
mercial payor database (Thomson Reuters MarketScan) to assemble
a cohort of patients who received HCT. The aim of our study was to
evaluate the feasibility of using this database to investigate costs over
the first 100 days after transplantation among adult and pediatric re-
cipients of allogeneic and autologous transplantation. Here we pres-
ent results for HCT hospitalization. MarketScan is a claims and
encounters database that includes specific health services records
for employees and their dependents in a selection of large employers,
health plans and government organizations. Claims and encounter
data are linked to detailed patient demographic and enrollment in-
formation across sites and types of providers. For our study, we
used ICD-9 diagnosis and procedure codes to identify HCT recipi-
ents. We identified 3816 patients who received HCT from 2007 to
2009; these patients accounted for 4026 HCT hospitalizations.
Among these, 41% were allogeneic HCT, 49% were autologous
HCT, and the type of HCTwas not specified in 9%. Themost com-
mon indication for allogeneic HCT was acute myeloid leukemia
(20%), and for autologous HCT multiple myeloma was most com-
mon (40%). The mean length of hospital stay was 30 (SD 20) days
for allogeneic and 19 (SD 11) days for autologous HCT recipients.
The mean age for allogeneic HCT recipients was 43 (SD 18) years,
while it was 51 (SD 16) years for autologous HCT recipients
(P\0.01). The mean costs of HCT hospitalizations was $196,307
for allogeneic and $96,153 for autologous HCT recipients. Our
study highlights the feasibility of using the MarketScan commercial
payor database to identify HCT recipients and to study costs of
HCT in the U.S. Ongoing analyses will describe total inpatient
and outpatient costs within the first 100 days of HCT and variations
in these costs by age group and geographic region.294
NOROVIRUS GASTROENTERITIS – AN EMERGING PATHOGEN IN PEDIAT-
RIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS
Ozdemir, N., Davies, S.M., Filipovich, A.H., Bleesing, J.J., Jodele, S.,
Grimley,M.S.,Marsh, R.A.,Myers, K.C.,Mehta, P.A. Cincinnati Child-
ren’s Hospital Medical Center, Cincinnati, OH
Background: Norovirus (family of the Calciviridae) infection is
a common cause of acute gastroenteritis, however, data on norovirus
infection is limited in immunocompromised patients. Here we re-
port our single center experience with norovirus infection in 12 pe-
diatric HSCT patients.
Methods: Patient demographics and transplant characteristics are
described in Table 1.
Table 1. PatientDemographics andTransplantCharacteristics
Sex/Age Donor Type of Concurrent
Patient #S314(years) Diagnosis type conditioning GVHDGut Skin Liver
1 M/1.0 HLH URD RIC + + -
2 F/1.6 SCID URD RIC - + -
3 M/9.6 Autoimmune
neutropenia
URD RIC - - -4 M/0.5 HLH MSD RIC - - -
5 M/22.1 MDS MSD MAC - - -
6 F/2.1 Ligase IV deficiency URD RIC - - -(Continued )Table 1. (Continued )Patient #
Sex/Age
(years) Diagnosis
Donor
type cType of
onditioning
Concurrent
GVHD7 M/0.7 WAS UCB MAC - + -
8 M/18.2 XLP URD RIC + - -
9 M/5.8 SCID URD RIC - + -10 F/11.4 CML URD MAC - - -
11 F/8.2 FA URD MAC - + -
12 M/1.7 HLH URD RIC - - -RIC: reduced-intensity conditioning, MAC: myeloablative conditioning;
HLH: hemophagocytic lymphohistiocytosis; SCID: severe combined im-
munodeficiency; MDS; myelodysplastic syndrome; WAS: Wiskott-Al-
drich syndrome; XLP: X-linked lymphoproliferative syndrome; CML:
Chronic myelogenous leukemia; FA: Fanconi anemia; URD: unrelated
donor; MSD: matched sibling donor; UCB: unrelated cord blood;
GVHD: graft versus host disease
Results: Twelve patients presented between January 2009-Septem-
ber 2011, with diarrhea. Most patients (9/12) also had significant
nausea and vomiting. At initial presentation, patients had diarrhea
for a median of 31 days (range: 3-72) and nausea/vomiting for 5
days (range: 1-30). One or more complications such as hypotension,
hypovolemic shock, protein losing enteropathy, pneumatosis intesti-
nalis occured in 9 patients, with 3 requiring transfer to intensive care
unit for the same. All 12 patients had positive stool PCR. Eight pa-
tients had prolonged PCR positivity for more than 3 months, and
one of them had intermittent shedding. These patients also had
a prolonged clinical course with persistent or intermittent diarrhea,
abdominal discomfort, nausea and vomiting. In total, 11 patients had
significant weight loss and required supplemental intravenous/en-
teral nutritional support. Five patients hadC. difficile and 4 had stool
adenovirus positivity around the time of norovirus infection, how-
ever, they remained symptomatic despite clearing C. difficile and ad-
enovirus in stool, correlating with persistent positive norovirus
PCRs. All 12 patients were treated with intravenous immunoglobu-
lin (IVIG) and 4 patients with severe or chronic course received 14
day course of nitazoxinide. Three out of 4 responded in terms of im-
proved/resolved symptoms. In patients treated only with IVIG sup-
port, 7/8 cleared acute symptoms, but only two who became PCR
negative, clearly had resolution of symptoms. Remaining 5 although
improved initially, continued to have low grade chronic symptoms
correlating with their PCR positivity.
Conclusion: Norovirus can have a prolonged chronic or relapsing
course with significant morbidity and potential mortality in children
undergoing HSCT. Treatment with IVIG and/or nitazoxinide ap-
pears to be effective in shortening the duration of symptoms. In ad-
dition, in our small cohort, achievement of PCR negativity seems to
correlate with resolution of illness. Prospective studies including
large number of patients are warranted to better understand norovi-
rus disease in HSCT setting.295
HUMAN BIOMARKER DISCOVERY AND PREDICTIVE MODELS OF DISEASE
PROGRESSION AND RESPONSE TO THERAPY FOR IDIOPATHIC PNEUMO-
NIA SYNDROME
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Ho, V.3, Chance, M.R.1, Cooke, K.R.4 1Case Western Reserve University,
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Idiopathic pneumonia syndrome (IPS) is a frequently fatal compli-
cation following allogeneic BMT (allo-BMT). Experimental models
have demonstrated a critical role for TNFa in the development of
IPS, but mechanisms responsible for human disease are poorly char-
acterized. Using samples collected from a pilot trial using etanercept
(Enbrel ) for IPS, we performed two separate label-free, proteo-
mics experiments utilizing liquid chromatography and mass spec-
trometry to define inflammatory pathways contributing to the
clinical syndrome. Allo-BMT recipients without complications
